Edico Genome And Fabric Genomics Develop Integrated Solution For Genomic Analysis With The Goal Of Improving Clinical Care

Share This.....Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Email this to someone

Industry Leaders Partner to Provide Streamlined Variant Data Analysis Solution

ORLANDO, Fla., Oct. 19, 2017 /PRNewswire/ — Today at the American Society for Human Genetics (ASHG) Annual Meeting, Edico Genome and Fabric Genomics announced their collaboration to provide an integrated solution for secondary and tertiary analysis of next-generation sequencing data. Through this partnership, users can seamlessly utilize Edico Genome’s DRAGENTM Bio-IT platform with Fabric Genomics’ Opal™ Clinical variant interpretation platform to accurately gain biological insights for both inherited disease and oncology, with the goal of improving patients’ clinical care.

The partnership is grounded in a successful implementation with Rady Children’s Institute for Genomic Medicine (RCIGM), which has utilized DRAGEN and Opal Clinical together for the past year. RCIGM, headed by Dr. Stephen Kingsmore, M.D., D.Sc., President and CEO, relies on the combined solution to deliver life-saving diagnoses for critically ill children in the neonatal intensive care unit (NICU) or pediatric intensive care unit (PICU), at a greatly expedited rate with industry leading accuracy. Read about RCIGM’s work with rapid whole genome sequencing (rWGS) in the September issue of TIME.

“Speed and accuracy are essential to distilling medically actionable information from whole genome sequencing,” said Dr. Kingsmore. “At Rady Children’s Institute for Genomic Medicine, DRAGEN and Opal Clinical are the core technologies that we rely upon for variant identification and interpretation. The results are helping physicians provide targeted treatment for critically ill children in the NICU and PICU.”

Edico Genome’s DRAGEN platform performs ultra-rapid secondary analysis, analyzing a whole human genome at 30x coverage in approximately 20 minutes. Due to its patented design, DRAGEN’s speed does not compromise accuracy, and the platform received high scores across all accuracy metrics in the recent PrecisionFDA Hidden Treasures – Warm Up Challenge. DRAGEN is available both onsite and in the Amazon Web Services’ (AWS) cloud, enabling the delivery of high accuracy and cost savings regardless of throughput.

“Whether analyzing thousands of genomes for a national genomics program or individual sequences to provide personalized insight, disjointed workflows reduce efficiency, resulting in time and money lost,” said Pieter van Rooyen, Ph.D., President and CEO at Edico Genome. “Our partnership with Fabric Genomics is one built on mutual dedication to accuracy, speed and data security, resulting in an ultra-rapid, highly accurate turnkey solution.”

Fabric Genomics uses machine learning to rapidly identify disease-causing variants through its two proprietary algorithms, VAAST and Phevor. Clinical research partnerships with pioneers RCIGM, Genomics England, and the Utah Genome Project have demonstrated that the two algorithms are essential for the successful identification of deleterious variants in critically ill children.

“Both Opal Clinical and DRAGEN were designed to forward the adoption of personalized medicine through faster, more accurate downstream analysis,” said Martin Reese, Ph.D., President and CEO at Fabric Genomics. “As we continue to strengthen our partnership with Edico Genome, we look forward to delivering enhanced integrated offerings and services in order to help discover disease-causing variants in children and help change treatment for the better.”

To learn more at ASHG this week, visit Edico Genome’s booth #710 and Fabric Genomics’ booth #513 in Orlando.

About Edico Genome

The use of next-generation sequencing is growing at an unprecedented pace, creating a need for easy to implement infrastructure that enables rapid, accurate, and cost-effective processing and storage of this big data. Edico Genome has created a patented end-to-end platform solution for analysis of next-generation sequencing data, DRAGEN™, which speeds whole genome data analysis from hours to minutes while delivering the industry’s highest accuracy and significantly reducing costs. Top clinicians and researchers are utilizing the platform, both onsite and in the Cloud, to achieve faster diagnoses for critically ill newborns, cancer patients and expecting parents waiting on prenatal tests, and faster results for scientists and drug developers. For more information, visit www.EdicoGenome.com or follow @EdicoGenome.

About Fabric Genomics

By accelerating access to insights related to the cause of genetic diseases, Fabric Genomics™ is leading the way in precision healthcare. Fabric Genomics is a global company offering end-to-end genomic data analysis, annotation, curation, classification, and reporting solutions to clinical labs, hospital labs, country sequencing programs, and life science companies. Fabric Genomics’ analytic capabilities cover the complete next-generation sequencing (NGS) workflow, between the sequencer and the clinical report. Its software is optimized for the analysis of panels, exomes, and genomes for hereditary diseases and oncology. We offer a comprehensive, secure platform and partner with clinical labs to help them interpret variants faster, integrate with EMRs, and ultimately sign out cases more efficiently. Fabric Genomics was founded by scientists and industry pioneers in bioinformatics, large-scale genomics, and clinical genetics, and is headquartered in Oakland, California. To learn more, visit www.fabricgenomics.com, and follow us on TwitterLinkedin, and Facebook.


SOURCE Edico Genome

CONTACT: Fabric Genomics, Vanessa Sawyer, Director of Global Marketing, (415) 574-0377, vsawyer@fabricgenomics.com or Edico Genome, Stephanie Black, Marketing Manager, (858) 722-3694, Stephanie.Black@edicogenome.com or Monica May for Edico Genome, Canale Communications, (619) 849-5383, monica@canalecomm.com